• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Spinal Muscular Atrophy Functional Composite Score Revised (SMA-FCR) in Untreated and Nusinersen-Treated Patient Cohorts.未治疗和接受诺西那生治疗的患者队列中的脊髓性肌萎缩症功能综合评分修订版(SMA-FCR)
Neurology. 2025 Jul 22;105(2):e213839. doi: 10.1212/WNL.0000000000213839. Epub 2025 Jun 27.
2
Systematic Review and Meta-analysis of Long-Term Nusinersen Effectiveness in Adolescents and Adults with Spinal Muscular Atrophy.脊髓性肌萎缩症青少年及成人长期使用诺西那生钠有效性的系统评价与荟萃分析
Adv Ther. 2025 Jun 27. doi: 10.1007/s12325-025-03260-1.
3
Longitudinal Assessment of 4-Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen.接受诺西那生治疗的脊髓性肌萎缩症II型和III型患者4年手功能模块评分变化的纵向评估
Eur J Neurol. 2025 Jul;32(7):e70268. doi: 10.1111/ene.70268.
4
Comparative efficacy of risdiplam and nusinersen in Type 2 and 3 spinal muscular atrophy patients: A cohort study using real-world data.利司扑兰与诺西那生在2型和3型脊髓性肌萎缩症患者中的疗效比较:一项使用真实世界数据的队列研究。
J Neuromuscul Dis. 2024 Nov;11(6):1190-1199. doi: 10.1177/22143602241288087. Epub 2024 Dec 20.
5
Difficulty of administration of nusinersen in complex-column spinal muscular atrophy: New alternative technique by means of cervical intrathecal access through an Ommaya reservoir.在复杂型脊髓性肌萎缩症中给予诺西那生的给药困难:通过奥马亚贮液器进行颈段鞘内给药的新替代技术。
Eur J Paediatr Neurol. 2025 Jan;54:107-112. doi: 10.1016/j.ejpn.2025.01.005. Epub 2025 Jan 10.
6
Cytokines in cerebrospinal fluid as a prognostic predictor after treatment of nusinersen in SMA patients.脑脊液细胞因子作为 SMA 患者接受 nusinersen 治疗后的预后预测指标。
Clin Neurol Neurosurg. 2024 Sep;244:108462. doi: 10.1016/j.clineuro.2024.108462. Epub 2024 Jul 19.
7
Quantitative cervical cord MRI in spinal muscular atrophy: a sensitive imaging biomarker of disease evolution and treatment.脊髓性肌萎缩症的定量颈髓MRI:疾病进展和治疗的敏感影像学生物标志物
J Neurol. 2025 Jun 24;272(7):475. doi: 10.1007/s00415-025-13205-x.
8
Spinal Muscular Atrophy脊髓性肌萎缩症
9
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
10
Efficacy of risdiplam in spinal muscular atrophy: A systematic review and meta-analysis.利司扑兰治疗脊髓性肌萎缩症的疗效:系统评价和荟萃分析。
Pharmacotherapy. 2024 Jan;44(1):97-105. doi: 10.1002/phar.2866. Epub 2023 Aug 21.

本文引用的文献

1
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study.确定未经治疗的脊髓性肌萎缩症患者扩展版 Hammersmith 功能性运动量表中的最小临床重要差异:一项国际研究。
Eur J Neurol. 2024 Aug;31(8):e16309. doi: 10.1111/ene.16309. Epub 2024 Apr 24.
2
Systematic Literature Review of the Natural History of Spinal Muscular Atrophy: Motor Function, Scoliosis, and Contractures.脊髓性肌萎缩症自然史的系统文献回顾:运动功能、脊柱侧凸和挛缩。
Neurology. 2023 Nov 21;101(21):e2103-e2113. doi: 10.1212/WNL.0000000000207878. Epub 2023 Oct 9.
3
Examination of Upper Limb Function and the Relationship with Gross Motor Functional and Structural Parameters in Patients with Spinal Muscular Atrophy.脊髓性肌萎缩症患者上肢功能检查及其与粗大运动功能和结构参数的关系
Biomedicines. 2023 Mar 24;11(4):1005. doi: 10.3390/biomedicines11041005.
4
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants.一大群未经治疗的2型和3型小儿脊髓性肌萎缩症参与者的修订哈默史密斯量表评分的两年变化情况。
J Clin Med. 2023 Feb 28;12(5):1920. doi: 10.3390/jcm12051920.
5
Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).利司扑兰治疗 2 型或非卧床 3 型脊髓性肌萎缩症患者的两年疗效和安全性。
J Neurol. 2023 May;270(5):2531-2546. doi: 10.1007/s00415-023-11560-1. Epub 2023 Feb 3.
6
Revised Hammersmith Scale for spinal muscular atrophy: Inter and intra-rater reliability and agreement.修订后的脊髓性肌萎缩症 Hammersmith 量表:信度和一致性的评估。
PLoS One. 2022 Dec 21;17(12):e0278996. doi: 10.1371/journal.pone.0278996. eCollection 2022.
7
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey.疾病修正疗法时代脊髓性肌萎缩症的流行率:意大利全国性调查。
Neurology. 2023 Mar 14;100(11):522-528. doi: 10.1212/WNL.0000000000201654. Epub 2022 Dec 2.
8
Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.在接受nusinersen 治疗的非瘫痪型 2 型和 3 型 SMA 患儿中上肢功能得到改善:前瞻性 3 年 SMArtCARE 登记研究。
Orphanet J Rare Dis. 2022 Oct 23;17(1):384. doi: 10.1186/s13023-022-02547-8.
9
Development of a functional composite for the evaluation of spinal and bulbar muscular atrophy.用于评估脊髓性肌萎缩症的功能性复合材料的开发。
Sci Rep. 2022 Oct 19;12(1):17443. doi: 10.1038/s41598-022-22322-w.
10
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes.修订后的 II 型和 III 型脊髓性肌萎缩上肢模块:24 个月的变化。
Neuromuscul Disord. 2022 Jan;32(1):36-42. doi: 10.1016/j.nmd.2021.10.009. Epub 2021 Nov 7.

未治疗和接受诺西那生治疗的患者队列中的脊髓性肌萎缩症功能综合评分修订版(SMA-FCR)

Spinal Muscular Atrophy Functional Composite Score Revised (SMA-FCR) in Untreated and Nusinersen-Treated Patient Cohorts.

作者信息

Pasternak Amy, McDermott Michael P, Montes Jacqueline, Glanzman Allan M, Coratti Giorgia, Dunaway Young Sally, Duong Trinh Tina, Martens William B, Day John W, Zolkipli-Cunningham Zarazuela, Sansone Valeria Ada, D'Amico Adele, Messina Sonia, Bruno Claudio, Mercuri Eugenio, De Vivo Darryl C, Darras Basil T

机构信息

Department of Physical and Occupational Therapy Services, Boston Children's Hospital, MA.

Department of Biostatistics and Compulational Biology, University of Rochester, NY.

出版信息

Neurology. 2025 Jul 22;105(2):e213839. doi: 10.1212/WNL.0000000000213839. Epub 2025 Jun 27.

DOI:10.1212/WNL.0000000000213839
PMID:40577678
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12205743/
Abstract

BACKGROUND AND OBJECTIVES

The Spinal Muscular Atrophy Functional Composite (SMA-FC) combines scores from the Hammersmith Functional Motor Scale Expanded (HFMSE), Upper Limb Module (ULM), and Six-Minute Walk Test (6MWT) into a single score and removes the floor and ceiling effects of the HFMSE. Our objective was to evaluate a revised version of the SMA-FC (SMA-FCR) by including the Revised ULM (RULM) in untreated and nusinersen-treated SMA.

METHODS

We included participants with HFMSE, RULM, and 6MWT data at the same visit. The SMA-FCR represented the average of the 3 test scores, each expressed as the percentage of the maximum possible score (HFMSE and RULM) or the percent of predicted normative performance (6MWT). Mean annual rates of change were calculated in participants who had SMA-FCR data at 2 or more visits while untreated and/or while treated.

RESULTS

There were 580 participants (49.6% female) with a mean (SD) age of 19.2 (15.5) years (range 1.3-70.6 years). The median (interquartile range) SMA-FCR scores were 3.6 (0.0-8.1) for nonsitters, 22.3 (16.3-31.2) for sitters, and 75.1 (63.7-86.6) for walkers. The SMA-FCR score reduced the ceiling effect seen with the RULM in walkers and the floor effect seen with the HFMSE in nonsitters. The mean annual rate of change in the SMA-FCR was -0.62 (95% CI -1.15 to -0.08, = 0.02) in untreated participants and 0.15 (95% CI -0.12 to 0.42, = 0.28) in treated participants (difference = 0.77, 95% CI 0.19-1.34, = 0.009). The mean annual rate of change in the HFMSE was -0.19 (95% CI -0.63 to 0.25, = 0.40) in untreated participants and -0.21 (95% CI -0.43 to 0.01, = 0.06) in treated participants (difference = -0.02, 95% CI -0.49 to 0.46, = 0.94).

DISCUSSION

The SMA-FCR broadens the spectrum of abilities captured in SMA. Analyses of the treated-untreated differences in mean annual rate of change suggest that the SMA-FCR may be more sensitive to change than the HFMSE. The use of the SMA-FCR in clinical trials might allow for study designs with broader eligibility criteria including weaker individuals who score minimally on the HFMSE and stronger individuals who score maximally on the RULM.

摘要

背景与目的

脊髓性肌萎缩症功能综合评分(SMA - FC)将汉默史密斯功能运动量表扩展版(HFMSE)、上肢模块(ULM)和六分钟步行试验(6MWT)的得分合并为一个单一分数,并消除了HFMSE的地板效应和天花板效应。我们的目的是通过在未治疗和接受诺西那生治疗的脊髓性肌萎缩症患者中纳入修订后的上肢模块(RULM)来评估SMA - FC的修订版(SMA - FCR)。

方法

我们纳入了在同一就诊时具有HFMSE、RULM和6MWT数据的参与者。SMA - FCR代表三个测试分数的平均值,每个分数表示为最大可能分数(HFMSE和RULM)的百分比或预测正常表现的百分比(6MWT)。在未治疗和/或治疗期间有两次或更多次就诊时具有SMA - FCR数据的参与者中计算平均年变化率。

结果

共有580名参与者(49.6%为女性),平均(标准差)年龄为19.2(15.5)岁(范围1.3 - 70.6岁)。非坐立者的SMA - FCR中位数(四分位间距)分数为3.6(0.0 - 8.1),坐立者为22.3(16.3 - 31.2),步行者为75.1(63.7 - 86.6)。SMA - FCR分数减少了步行者中RULM所见的天花板效应和非坐立者中HFMSE所见的地板效应。未治疗参与者的SMA - FCR平均年变化率为 - 0.62(95%置信区间 - 1.15至 - 0.